IL16 and Thrombocytopenia: Patients with stomach and colorectal cancers have been reported to have CRS evidenced by raised inflammatory markers, thrombocytopenia, elevated cytokine levels (IFN-γ/IL-2R/IL-18/IL-16/IL-10), and steroid responsiveness [50].